Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelabresib plus ruxolitinib versus placebo plus ruxolitinib in JAK inhibitor-naive myelofibrosis
2025-523555-66-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF) comparing Pelabresib + ruxolitinib with Placebo + ruxolitinib (2 arms). Primary endpoints: Spleen volume response at Week 24 and Change in total symptom score at Week 24. Planned start Sep 2026; status: authorised.
02
Drugs
pelabresibruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2025-523555-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523555-66-00.